Although the clinical potential of PARP-1 inhibitors is unquestionable with more than 100 ongoing clinical trials in both solid tumours and hematologic malignancies (clinicaltrials.gov accessed on 11 November 2021), many PARP-1 inhibitors have poor selectivity [22,23]. The gene discussed is PARP1; the disease is hematologic disorder.